Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.59 |
| ▸ | ICMT | O60725 | 2/20 | 0.57 |
| ▸ | CNR2 | P34972 | 10/20 | 0.52 |
| ▸ | CNR1 | P21554 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15747750 | 0.92 | CDC25A (0.67) | CDC25AICMTCNR2CNR1KDM4E | |
| SCHEMBL21535335 | 0.91 | CDC25A (0.73) | CDC25AICMTCNR2CNR1 | |
| SCHEMBL15747719 | 0.90 | CDC25A (0.75) | CDC25AICMTCNR2CNR1 | |
| SCHEMBL17102877 | 0.90 | CDC25A (0.75) | CDC25AICMTCNR2CNR1 | |
| SCHEMBL28836620 | 0.89 | CDC25A (0.52) | CDC25AICMTCNR2CNR1GAA | |
| SCHEMBL13228230 | 0.89 | NR4A2 (0.61) | CDC25AICMTCNR2CNR1GAA | |
| SCHEMBL28836439 | 0.88 | CDC25A (0.51) | CDC25AICMTCNR2CNR1GAA | |
| SCHEMBL28836606 | 0.84 | TSHR (0.53) | CDC25AICMTCNR2CNR1GAA | |
| SCHEMBL15747715 | 0.84 | CDC25A (0.80) | CDC25AICMTCNR2CNR1CREBBP | |
| SCHEMBL8690315 | 0.83 | S1PR2 (0.58) | CDC25AGAAKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12139459-B2 | Enhancer of fertilization function of sperm | TOHOKU UNIVERSITY (JP) | 2024-11-12 | — | — | US | disclosed |
| US-20220106270-A1 | ENHANCER OF FERTILIZATION FUNCTION OF SPERM | KAKE EDUCATIONAL INSTITUTION (JP) | 2022-04-07 | — | — | US | disclosed |
| CN-113292557-B | Pyridopyrimidinone mesoion derivative containing indole unit and preparation method and application thereof | 贵州大学 | 2022-02-11 | — | — | CN | disclosed |
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | TOHOKU UNIVERSITY (JP) | 2021-10-19 | — | — | US | disclosed |
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | TOHOKU UNIVERSITY (JP) | 2021-10-19 | — | — | US | disclosed |
| CN-113292557-A | Pyridopyrimidinone mesoion derivative containing indole unit and preparation method and application thereof | 贵州大学 | 2021-08-24 | — | — | CN | disclosed |
| US-10463647-B2 | Erythropoietin expression promoter | TOHOKU UNIVERSITY (JP) | 2019-11-05 | — | — | US | disclosed |
| US-10463647-B2 | Erythropoietin expression promoter | TOHOKU UNIVERSITY (JP) | 2019-11-05 | — | — | US | disclosed |
| US-20190224165-A1 | Agent for Preventing or Ameliorating Hearing Impairment | TOHOKU UNIVERSITY (JP) | 2019-07-25 | — | — | US | disclosed |
| US-20190224165-A1 | Agent for Preventing or Ameliorating Hearing Impairment | TOHOKU UNIVERSITY (JP) | 2019-07-25 | — | — | US | disclosed |
| US-20180353475-A1 | Erythropoietin Expression Promoter | KAKE EDUCATIONAL INSTITUTION (JP) | 2018-12-13 | — | — | US | disclosed |
| EP-2923700-B1 | ERYTHROPOIETIN EXPRESSION PROMOTER | UNIV TOHOKU (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-10004718-B2 | Erythropoietin expression promoter | TOHOKU UNIVERSITY (JP) | 2018-06-26 | — | — | US | disclosed |
| US-10004718-B2 | Erythropoietin expression promoter | TOHOKU UNIVERSITY (JP) | 2018-06-26 | — | — | US | disclosed |
| US-10004718-B2 | Erythropoietin expression promoter | TOHOKU UNIVERSITY (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20150353489-A1 | Erythropoietin Expression Promoter | KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION KANAGAWA CHILDREN'S MEDICAL CENTER (JP) | 2015-12-10 | — | — | US | disclosed |
| US-20150353489-A1 | Erythropoietin Expression Promoter | KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION KANAGAWA CHILDREN'S MEDICAL CENTER (JP) | 2015-12-10 | — | — | US | disclosed |
| US-20150353489-A1 | Erythropoietin Expression Promoter | KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION KANAGAWA CHILDREN'S MEDICAL CENTER (JP) | 2015-12-10 | — | — | US | disclosed |
| EP-2923700-A1 | ERYTHROPOIETIN EXPRESSION PROMOTER | Tohoku University (JP) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014080640-A1 | ERYTHROPOIETIN EXPRESSION PROMOTER | 国立大学法人東北大学 (JP) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180353475-A1 | Erythropoietin Expression Promoter | EPOR, NFE2L2, FOXO1 | CDC25A 1969/4885ICMT 3976/4885CNR2 3518/4885 |
| US-12139459-B2 | Enhancer of fertilization function of sperm | CATSPER1, NASP, ZP1 | CDC25A 3493/4885ICMT 2177/4885CNR2 3607/4885 |
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | SLC26A4, OTC, SLC25A20 | CDC25A 3942/4885ICMT 1421/4885CNR2 3704/4885 |
| US-20150353489-A1 | Erythropoietin Expression Promoter | EPOR, NFE2L2, FOXO1 | CDC25A 1969/4885ICMT 3976/4885CNR2 3518/4885 |
| US-20220106270-A1 | ENHANCER OF FERTILIZATION FUNCTION OF SPERM | CATSPER1, NASP, ZP1 | CDC25A 3493/4885ICMT 2177/4885CNR2 3607/4885 |
| US-20190224165-A1 | Agent for Preventing or Ameliorating Hearing Impairment | SLC26A4, OTC, SLC25A20 | CDC25A 3942/4885ICMT 1421/4885CNR2 3704/4885 |
| US-10004718-B2 | Erythropoietin expression promoter | EPOR, NFE2L2, FOXO1 | CDC25A 1969/4885ICMT 3976/4885CNR2 3518/4885 |
| US-10463647-B2 | Erythropoietin expression promoter | EPOR, NFE2L2, FOXO1 | CDC25A 1969/4885ICMT 3976/4885CNR2 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.